CoreWeave stock tumbles after Blue Owl financing report rattles AI data-center trade

February 21, 2026
CoreWeave stock tumbles after Blue Owl financing report rattles AI data-center trade

New York, February 20, 2026, 18:41 ET — After-hours

  • CoreWeave dropped 8.1% in after-hours, landing at $89.25. Shares fluctuated between $84.50 and $98.30 during the session.
  • Questions about how AI infrastructure projects get funded are surfacing again after a report detailed debt financing for a Pennsylvania data-center linked to Blue Owl.
  • CoreWeave’s results on Feb. 26 are next up, with investors watching for any signals on demand, spending, and how the company is approaching financing.

CoreWeave (CRWV.O) dropped 8.1% to $89.25 in Friday’s after-hours session, with the stock sinking as low as $84.50 before paring some losses. Fresh doubts over financing for a major data-center project rattled investors.

Here’s the core concern: AI data centers burn through cash. Should lenders pull back, it doesn’t mean projects stop—it just means borrowing costs climb, schedules drag out, and those big growth narratives begin to seem less sturdy.

That’s critical for CoreWeave—investors see access to funding as baked into the offering. The company’s story depends on ramping up capacity quickly to handle demand for graphics chips and power-hungry AI workloads.

Blue Owl Capital has disputed claims it couldn’t line up funding for the $4 billion Pennsylvania data-center project it’s building alongside CoreWeave. “Our sole obligation is to provide about $500 million of bridge financing through March 2026,” the firm said. Reuters

Lenders weren’t rushing to back the Lancaster, Pennsylvania project, according to Business Insider, citing concerns with CoreWeave’s credit standing. The outlet quoted BMO Capital Markets equity analyst Brennan Hawken, who covers Blue Owl, warning: “If there is a struggle to find the debt financing, that’s a red flag.” Business Insider

The tension was clear in the options pits, too. Friday saw contracts changing hands at a brisk pace, well above the norm. Implied volatility spiked, signaling traders were bracing for wider swings in the stock’s daily moves.

A Thursday Form 4 revealed Chief Development Officer Brannin McBee unloaded 33,315 Class A shares, trades carried out under a Rule 10b5-1 plan—one of those pre-set insider selling arrangements.

CoreWeave provides cloud infrastructure geared toward artificial intelligence, specializing in computing and software for model training and inference.

This isn’t only about a single location. Investors waste no time pulling back from the AI infrastructure theme when cash dries up, particularly for ventures that depend on layered partnerships and tapping debt markets.

The situation could reverse quickly. Should CoreWeave or its partners lay out solid funding plans or reveal strong demand to justify the investment, that recent slide in the stock might disappear. Without that, investors face worries over pricier debt and delays in expansion, threatening growth projections.

CoreWeave reports fourth-quarter results Feb. 26. Investors want numbers on capacity gains, more on power supply, and specifics about funding as the company gears up for spring expansion.

Technology News Today

  • Researchers Grow Soft, Wire-Free Brain Electrodes Inside Mice
    April 13, 2026, 7:11 PM EDT. Scientists at Purdue University report a method to grow soft, wire-free brain interfaces inside living mice. A single injection triggers blood proteins to assemble injected chemicals into a flexible electrode mesh that wraps around neurons. When illuminated with near-infrared light, the mesh dampens hyperactive cells. The technique avoids surgical insertion and tissue damage typical of rigid implants that can scar and fail. Conventional implants either record brain signals or stimulate activity and often require invasive surgery. By forming electrodes in situ, doctors could tailor neural interfaces after injection and tune brain activity remotely with light. Experts describe the work as a step toward integrating biocompatible materials with brain tissue, though real-world use remains years away.